Search
EU health policy: limited scope, high ambition
Over the past decades, the European Union (EU) has become more involved in public health policy. A recent study showed that a majority of policymakers even identifies EU health policy as a priority for 2020-20241.
Read moreMeet Helen Papadaki, our January volunteer of the month
Can you tell us what you do for EHA and when you started?
I am currently a Councilor of the EHA Board for the period 2016-2020, chair of the EHA Membership Committee and vice-chair of the Scientific Working Group (SWG) on…
Meet Helen Papadaki, our January volunteer of the month
Can you tell us what you do for EHA and when you started?
I am currently a Councilor of the EHA Board for the period 2016-2020, chair of the EHA Membership Committee and vice-chair of the Scientific Working Group (SWG) on…
Uptake of CAR T cell therapy in Europe
Gene (editing) therapy continues to break ground in hematology, showing promising results in tackling severe blood cancers. Yet, its uptake in the European Union is slow, with few patients benefiting from it so far.
Read moreThe 'i4MDS' consortium looks to the future at its second general meeting
The International Integrative Innovative Immunology for Myelodysplastic Neoplasms consortium—also known as ‘i4MDS’—held its second general meeting in The Hague from February 9–10, 2024.
Read moreEuropean Reference Networks, a unique opportunity to take collaboration and patient care in hematology to the next level, was a core topic at EHA 2016
On Saturday 11 June, a session in the Patient Advocacy Track focused on the emerging European Reference Networks (ERNs).
Read moreMeet Robin Foà, our Volunteer of the Month
Can you tell us what you do for EHA and when you started?
I have been a member of EHA from its beginning and have participated in all EHA Congresses.
Meet Robin Foà, our Volunteer of the Month
Can you tell us what you do for EHA and when you started?
I have been a member of EHA from its beginning and have participated in all EHA Congresses.
Without access to treatment, can we truly innovate in rare diseases?
Interview with Giampaolo Merlini
There have been many developments on rare diseases since the EU Orphan Medicinal Products Regulation came into force in 2000. As the European Commission is evaluating its effectiveness, EHA discussed with Prof.
Recap: European Affairs and Hematology at EHA2024
As at previous congresses, the European Affairs track at EHA2024 offered opportunities to learn, exchange, and connect.
Read more